Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Liabilities and Shareholders Equity (2016 - 2020)

Historic Liabilities and Shareholders Equity for Larimar Therapeutics (LRMR) over the last 8 years, with Q3 2020 value amounting to $114.0 million.

  • Larimar Therapeutics' Liabilities and Shareholders Equity rose 2268.35% to $114.0 million in Q3 2020 from the same period last year, while for Dec 2020 it was $313.1 million, marking a year-over-year increase of 30.72%. This contributed to the annual value of $5.2 million for FY2019, which is 9572.86% down from last year.
  • Latest data reveals that Larimar Therapeutics reported Liabilities and Shareholders Equity of $114.0 million as of Q3 2020, which was up 2268.35% from $125.5 million recorded in Q2 2020.
  • Larimar Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $170.0 million for Q1 2016, and its period low was $5.2 million during Q4 2019.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $110.2 million (2019), whereas its average is $109.5 million.
  • In the last 5 years, Larimar Therapeutics' Liabilities and Shareholders Equity soared by 3706.58% in 2018 and then tumbled by 9572.86% in 2019.
  • Quarter analysis of 5 years shows Larimar Therapeutics' Liabilities and Shareholders Equity stood at $131.6 million in 2016, then fell by 19.84% to $105.5 million in 2017, then increased by 15.4% to $121.8 million in 2018, then plummeted by 95.73% to $5.2 million in 2019, then surged by 2091.06% to $114.0 million in 2020.
  • Its last three reported values are $114.0 million in Q3 2020, $125.5 million for Q2 2020, and $73.7 million during Q1 2020.